DOM: Observation on the efficacy and safety of basal insulin combined with oral drugs in the treatment of patients with type 2 diabetes by changing the basal insulin to 300U/mL glargine

 Effective blood sugar control is essential to prevent or delay the complications of diabetes and help extend life expectancy
.

The recommended treatment for type 2 diabetes (T2D) includes gradual life>

If dual or triple OAD treatment and/or GLP-1 receptor agonists do not reach the individual HbA1c target after the last 3-6 months, it is recommended to initiate basal insulin (BI)-supported oral therapy (BOT) in global and local guidelines ) Treatment enhancement

Materials and methods: This 12-month non-interventional, multi-center, prospective study in Germany, Austria and Switzerland recorded T2D patients with glycosylated hemoglobin (HbA1c) between 7.
5-10.
0%.
After deciding to change BI to GLA-300, she is currently undergoing non-GLA-300 BOT treatment
.

The primary endpoint is the proportion of patients with a fasting blood glucose goal of ≤110 mg/dL

Results: 1194 participants formed a complete analysis set, of which 793 completed 12 months of GLA-300 treatment (Fas-M12) records
.

The main BI in the past was insulin glargine 100 U/mL (GLA-100; 47.

Table: The incidence of hypoglycemia before using GLA-300, 6 months after using GLA-300, and 12 months after using GLA-300 (within the last 12 weeks), and the incidence of hypoglycemia and 12 months after using GLA-300.
Incidence rate (Fas-M12)

Table: The incidence of hypoglycemia before using GLA-300, 6 months after using GLA-300, and 12 months after using GLA-300 (within the last 12 weeks), and the incidence of hypoglycemia and 12 months after using GLA-300.
Incidence rate (Fas-M12)

Figure 1 Fasting blood glucose (≤110 mg/dL[≤6.
1 mmol/L]) and glycosylated hemoglobin (individual) target achievement rate (Fas-M12; n =793); #, the number of patients with 12-month data; the primary endpoint marked with a green box; Fas-M12, a complete analysis set with 12-month data; fasting blood glucose; Gla300, insulin glargine 300U/mL; 7 Evaluation after -12 months: Include all patients whose parameters have reached the goal during this period, that is, reach the goal for the first time, from 1-6 months to 1-6 months or occur and end within 1-6 months Patients who achieved their goals for the second time
.

Figure 1 Fasting blood glucose (≤110 mg/dL[≤6.
1 mmol/L]) and glycosylated hemoglobin (individual) target achievement rate (Fas-M12; n =793); #, the number of patients with 12-month data; the primary endpoint marked with a green box; Fas-M12, a complete analysis set with 12-month data; fasting blood glucose; Gla300, insulin glargine 300U/mL; 7 Evaluation after -12 months: Include all patients whose parameters have reached the goal during this period, that is, reach the goal for the first time, from 1-6 months to 1-6 months or occur and end within 1-6 months Patients who achieved their goals for the second time
.

Figure 2 (A) Glycated hemoglobin (HbA1c) and (B) fasting blood glucose (Fas-M12; n=793) after 12 months of basal insulin therapy (Fas-M12; n=793); *p<0.
0001; **p=0.
0011; *p=0.
0103;#, the number of patients with 12-month data

Figure 2 (A) Glycated hemoglobin (HbA1c) and (B) fasting blood glucose (Fas-M12; n=793) after 12 months of basal insulin therapy (Fas-M12; n=793); *p<0.
0001; **p=0.
0011; *p=0.
0103;#, the number of patients with 12-month data

Conclusion: Changing BI to GLA-300 in the BOT regimen can improve the metabolic control and treatment satisfaction of a considerable proportion of T2D patients, and the goals are not fully achieved in clinical practice within 12 months, symptoms and nighttime hypoglycemia The risk is reduced, and there is no weight gain
.

Changing the BI to GLA-300 in the BOT program can improve the metabolic control and treatment satisfaction of a considerable proportion of T2D patients, and the goals are not fully achieved in clinical practice within 12 months, and the symptoms and the risk of nocturnal hypoglycemia are reduced.
, And there is no weight gain
.

Original source:

Seufert J, Wiesli P, Fritsche A,et al, Switching the Basal Insulin to Insulin Glargine 300 U/mL in People with Type 2 Diabetes under Basal Insulin Supported Oral Therapy-Observational Trial on Effectiveness and Safety .

Switching the Basal Insulin to Insulin Glargine 300 U/mL in People with Type 2 Diabetes under Basal Insulin Supported Oral Therapy-Observational Trial on Effectiveness and Safety

 

Leave a message here